Literature DB >> 33862490

Preclinical data and safety assessment of phage therapy in humans.

Janet Y Nale1, Martha Rj Clokie2.   

Abstract

Bacteriophages (phages) are natural biological entities that kill bacteria with species specific precision, rendering them attractive for therapeutic purposes. Phages were discovered over a century ago, but, after antibiotic discovery, their use as antimicrobials dwindled. Interest in phage therapy has, however, been rekindled by increasing multi-drug resistance to routine and frontline antibiotics and by the slowing of antibiotic innovations. To build on fundamental phage research studies and compassionate usage, information on safety and efficacy of phages is needed to motivate clinical trials and are necessary for phage therapy to become mainstream. In this review, we discussed essential phage characterisation parameters alongside the merits and limitations of state-of-the-art models to gather preclinical data on the safety and efficacy of phage therapeutics. Crown
Copyright © 2021. Published by Elsevier Ltd. All rights reserved.

Entities:  

Year:  2021        PMID: 33862490     DOI: 10.1016/j.copbio.2021.03.002

Source DB:  PubMed          Journal:  Curr Opin Biotechnol        ISSN: 0958-1669            Impact factor:   9.740


  11 in total

Review 1.  Biological foundations of successful bacteriophage therapy.

Authors:  Carola Venturini; Aleksandra Petrovic Fabijan; Alicia Fajardo Lubian; Stefanie Barbirz; Jonathan Iredell
Journal:  EMBO Mol Med       Date:  2022-05-27       Impact factor: 14.260

2.  Solvent Extraction of Klebsiella pneumoniae Bacteriophage Lysates with 1-Dodecanol Results in Endotoxin Reduction with Low Risk of Solvent Contamination.

Authors:  Jordyn Michalik-Provasek; Harley Parker; Lauren Lessor; Jason J Gill
Journal:  Phage (New Rochelle)       Date:  2021-09-17

3.  Impact of Phage CDHS-1 on the Transcription, Physiology and Pathogenicity of a Clostridioides difficile Ribotype 027 Strain, R20291.

Authors:  Janet Y Nale; Thekra Sideeq Al-Tayawi; Shaun Heaphy; Martha R J Clokie
Journal:  Viruses       Date:  2021-11-11       Impact factor: 5.048

Review 4.  Phage therapy for secondary bacterial infections with COVID-19.

Authors:  Nannan Wu; Li-Kuang Chen; Tongyu Zhu
Journal:  Curr Opin Virol       Date:  2021-11-09       Impact factor: 7.090

Review 5.  Phage Revolution Against Multidrug-Resistant Clinical Pathogens in Southeast Asia.

Authors:  Mark B Carascal; Donna May Dela Cruz-Papa; Roland Remenyi; Mely Cherrylynne B Cruz; Raul V Destura
Journal:  Front Microbiol       Date:  2022-01-27       Impact factor: 5.640

6.  A Multiwell-Plate Caenorhabditis elegans Assay for Assessing the Therapeutic Potential of Bacteriophages against Clinical Pathogens.

Authors:  Prasanth Manohar; Belinda Loh; Namasivayam Elangovan; Archana Loganathan; Ramesh Nachimuthu; Sebastian Leptihn
Journal:  Microbiol Spectr       Date:  2022-02-16

Review 7.  T7 Phage as an Emerging Nanobiomaterial with Genetically Tunable Target Specificity.

Authors:  Hui Yue; Yan Li; Mingying Yang; Chuanbin Mao
Journal:  Adv Sci (Weinh)       Date:  2021-12-16       Impact factor: 16.806

Review 8.  A Phage Foundry Framework to Systematically Develop Viral Countermeasures to Combat Antibiotic-Resistant Bacterial Pathogens.

Authors:  Vivek K Mutalik; Adam P Arkin
Journal:  iScience       Date:  2022-03-19

9.  Two Newly Isolated Enterobacter-Specific Bacteriophages: Biological Properties and Stability Studies.

Authors:  Martyna Cieślik; Marek Harhala; Filip Orwat; Krystyna Dąbrowska; Andrzej Górski; Ewa Jończyk-Matysiak
Journal:  Viruses       Date:  2022-07-12       Impact factor: 5.818

10.  Preclinical Assessment of Bacteriophage Therapy against Experimental Acinetobacter baumannii Lung Infection.

Authors:  Sandra-Maria Wienhold; Markus C Brack; Geraldine Nouailles; Gopinath Krishnamoorthy; Imke H E Korf; Claudius Seitz; Sarah Wienecke; Kristina Dietert; Corinne Gurtner; Olivia Kershaw; Achim D Gruber; Anton Ross; Holger Ziehr; Manfred Rohde; Jens Neudecker; Jasmin Lienau; Norbert Suttorp; Stefan Hippenstiel; Andreas C Hocke; Christine Rohde; Martin Witzenrath
Journal:  Viruses       Date:  2021-12-24       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.